Synaptogenix (NASDAQ:TAOX – Get Free Report) posted its quarterly earnings data on Monday. The company reported $0.38 earnings per share (EPS) for the quarter, Zacks reports. The company had revenue of $0.25 million for the quarter. Synaptogenix had a negative net margin of 768.22% and a negative return on equity of 68.93%.
Synaptogenix Trading Up 0.5%
Synaptogenix stock opened at $1.87 on Wednesday. The firm has a 50 day moving average of $3.51 and a 200 day moving average of $4.13. The firm has a market capitalization of $15.03 million, a price-to-earnings ratio of -0.49 and a beta of 1.81. Synaptogenix has a 12-month low of $1.70 and a 12-month high of $7.85.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on TAOX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Synaptogenix in a report on Thursday, October 15th. Wall Street Zen downgraded shares of Synaptogenix from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the stock has an average rating of “Sell”.
Synaptogenix Company Profile
Synaptogenix was a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases and disorders involving impaired cognitive function. The company’s research centered on therapies intended to support synaptic function. Its lead investigational drug candidate was bryostatin-1, which it studied as a potential treatment for Alzheimer’s disease. The company also explored its approach in other conditions associated with cognitive impairment. Bryostatin-1 was investigational, not an approved medicine.
Read More
- Five stocks we like better than Synaptogenix
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
